Article Figures & Data
Figures
- Fig 1.
Unregistered sequences of a representative subject acquired before treatment (t0, top row) and 2 weeks after initiation of therapy (t1, bottom row). Acquisitions include postcontrast T1-weighted with fat-saturation (A and D), T2-weighted with fat-saturation (B and E), and DCE MR imaging (C and F). Manually defined primary gross tumor volumes are depicted for each time point (yellow lines). The images above are those of subject 10, a survivor at follow-up.
- Fig 2.
Unregistered sequences of a representative subject acquired before treatment (t0, top row) and 2 weeks after initiation of therapy (t1, bottom row). Acquisitions include postcontrast T1-weighted with fat-saturation (A and D), T2-weighted with fat-saturation (B and E), and DCE MR imaging (C and F). Manually defined primary gross tumor volumes are depicted for each time point (yellow lines). The images above are those of subject 3, a nonsurvivor at follow-up.
- Fig 3.
ROC curves for PRMKtrans− (blue line) and PRMKtrans0 (green line) at 2 weeks after treatment initiation (A). Kaplan-Meier survival plots for overall survival as a function of stratification by PRMKtrans− (the perfusion parameter most predictive of survival) at 2 weeks after treatment initiation (B). The blue line represents PRMKtrans− ≤ the cutoff. The green line represents PRMKtrans− > the cutoff.
- Fig 4.
Representative patients with HNSCC stratified by PRMKtrans− as survivor (top row, median survival time, 64.9 months) or nonsurvivor (bottom row, median survival time, 10.3 months) at the time of analysis. PRMKtrans color-coded ROIs are superimposed on pretreatment T1-weighted gadolinium contrast-enhanced images (A and C). The scatterplots illustrate the distribution of changes in Ktrans throughout the entire volumes of interest (B and D). The 95% confidence intervals within the scatterplots are represented by the black lines. Voxels with significantly increasing, decreasing, or unchanged Ktrans are coded as red, blue, and green dots, respectively.
Tables
Subject Age (yr)/Sex Primary Location Stage Status Survival (mo) Outcome 1 62/M Tonsil T1 N2a NED 75.4 Survivor 2 65/F Soft palate T2 N3 LF 3.5 Nonsurvivor 3 58/M Hypopharynx T4 N2b LF/RF/DF 10.3 Nonsurvivor 4 83/M Larynx T4 N0 LF 2.0 Nonsurvivor 5 43/M Tongue base/tonsil T4 N2c DF 4.6 Nonsurvivor 6 61/F Tonsil T2 N3 RF 66.1 Survivor 7 55/M Piriform sinus T2 N2b Unknown 33.5 Survivor 8 43/M Tonsil T2 N2b DF 18.9 Nonsurvivor 9 57/M Nasopharynx T2 N2b NED 56.4 Survivor 10 60/M Tongue base T3 N0 NED 64.9 Survivor Note:—NED indicates no evidence of disease; LF, local failure; RF, regional failure; DF, distant failure.
Jump to section
Related Articles
Cited By...
- No citing articles found.